FindTrial
Sign In

Prospective study of sclerotherapy in patients of portal hypertension observational study

Prospective study of sclerotherapy in patients of portal hypertension observational study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/10/075013
Enrollment
25
Registered
2024-10-09
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K23- Disorders of esophagus in diseasesclassified elsewhere Health Condition 2: K23- Disorders of esophagus in diseasesclassified elsewhere

Interventions

Intervention1: Sclerotherapy Given: Polidocanol 3% Will Be The Sclerosant Administered To Oesophageal Varices

Sponsors

Bhayani Vishal Babubhai
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patienrt With Varices Who Give Consent For Sclerotherapy

Exclusion criteria

Exclusion criteria: Pregnant Women Patient With Comorbidities Such As Bledding Disorder

Design outcomes

Primary

MeasureTime frame
To Assess The Effectiveness Of Sclerotherapy In Case of Patient of Portal HypertensionTimepoint: 12 Months—

Secondary

MeasureTime frame
Numbers Of The Patient Showing Eradication Of VaricesTimepoint: 12 Months—

Countries

India

Contacts

Public ContactBhayani Vishal Babubhai

Sir T Hospital Bhavnagar

Drvikram006gohil@gmail.com8758767821

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026